Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

Michael Koch, Jane S. Cho, Hristos Kaimakliotis, Liang Cheng, Zaina Sangale, Michael Brawer, William Welbourn, Julia Reid, Steven Stone

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging. OBJECTIVE:We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP. METHODS: Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group. RESULTS: Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031). CONCLUSIONS: Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalCancer Biomarkers
Volume17
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Cell Cycle
Radiation
Recurrence
Prostatectomy
Salvage Therapy
Radiotherapy
RNA
Neoplasm Grading
Logistic Models
Gene Expression

Keywords

  • biochemical recurrence
  • cell cycle progression score
  • Prostate cancer
  • prostatectomy
  • salvage radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. / Koch, Michael; Cho, Jane S.; Kaimakliotis, Hristos; Cheng, Liang; Sangale, Zaina; Brawer, Michael; Welbourn, William; Reid, Julia; Stone, Steven.

In: Cancer Biomarkers, Vol. 17, No. 1, 2016, p. 83-88.

Research output: Contribution to journalArticle

Koch, Michael ; Cho, Jane S. ; Kaimakliotis, Hristos ; Cheng, Liang ; Sangale, Zaina ; Brawer, Michael ; Welbourn, William ; Reid, Julia ; Stone, Steven. / Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. In: Cancer Biomarkers. 2016 ; Vol. 17, No. 1. pp. 83-88.
@article{e6f8456080fd49c7b233921095996b67,
title = "Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence",
abstract = "BACKGROUND: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging. OBJECTIVE:We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP. METHODS: Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group. RESULTS: Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031). CONCLUSIONS: Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.",
keywords = "biochemical recurrence, cell cycle progression score, Prostate cancer, prostatectomy, salvage radiotherapy",
author = "Michael Koch and Cho, {Jane S.} and Hristos Kaimakliotis and Liang Cheng and Zaina Sangale and Michael Brawer and William Welbourn and Julia Reid and Steven Stone",
year = "2016",
doi = "10.3233/CBM-160620",
language = "English (US)",
volume = "17",
pages = "83--88",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

AU - Koch, Michael

AU - Cho, Jane S.

AU - Kaimakliotis, Hristos

AU - Cheng, Liang

AU - Sangale, Zaina

AU - Brawer, Michael

AU - Welbourn, William

AU - Reid, Julia

AU - Stone, Steven

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging. OBJECTIVE:We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP. METHODS: Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group. RESULTS: Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031). CONCLUSIONS: Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.

AB - BACKGROUND: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging. OBJECTIVE:We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP. METHODS: Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group. RESULTS: Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031). CONCLUSIONS: Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.

KW - biochemical recurrence

KW - cell cycle progression score

KW - Prostate cancer

KW - prostatectomy

KW - salvage radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84978484060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978484060&partnerID=8YFLogxK

U2 - 10.3233/CBM-160620

DO - 10.3233/CBM-160620

M3 - Article

C2 - 27314296

AN - SCOPUS:84978484060

VL - 17

SP - 83

EP - 88

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 1

ER -